The central role of SOCS-3 in integrating the neuro-immunoendocrine interface.

Cytokines and related signaling molecules lead to profound regulatory changes in differentiated cell function, modulating immune functions, the stress response, energy metabolism, growth, and reproduction. A network of intracellular molecules that dampen or inhibit the effects of these pleiotropic factors provides a crucial counterbalance to cytokine signals. Recent studies have shown that negative feedback, initiated in the various target tissues by the cytokines themselves, is central to endocrine homeostasis. Cytokine-mediated adrenocorticotropin hormone (ACTH) and cortisol overproduction, for instance, is prevented by tightly regulated cytokine-induced intracellular negative control systems. Likewise, growth hormone (GH) signaling is abrogated by cytokine-induced proteins, providing an explanation for GH resistance and stunted growth observed in states of elevated cytokine activity, including inflammation, starvation, and chronic illness. This article explores the role of the signal suppressor SOCS-3 in inhibiting the actions of neuro-endocrine cytokines and hormones, while maintaining the plasticity of the ultimate neuro-immune endocrine responses.

[1]  E. Arzt gp130 cytokine signaling in the pituitary gland: a paradigm for cytokine-neuro-endocrine pathways. , 2001, The Journal of clinical investigation.

[2]  S. Melmed,et al.  cAMP neuropeptide agonists induce pituitary suppressor of cytokine signaling-3: novel negative feedback mechanism for corticotroph cytokine action. , 2001, Molecular endocrinology.

[3]  K. Nakao,et al.  Induction of JAB/SOCS-1/SSI-1 and CIS3/SOCS-3/SSI-3 Is Involved in gp130 Resistance in Cardiovascular System in Rat Treated With Cardiotrophin-1 In Vivo , 2001, Circulation research.

[4]  R. Unger,et al.  The role of leptin resistance in the lipid abnormalities of aging , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  W. Leonard,et al.  JAB/SOCS1/SSI-1 is an interleukin-2-induced inhibitor of IL-2 signaling. , 2001, Blood.

[6]  J. Flier,et al.  SOCS3 Mediates Feedback Inhibition of the Leptin Receptor via Tyr985 * , 2000, The Journal of Biological Chemistry.

[7]  S. Melmed,et al.  Direct regulation of pituitary proopiomelanocortin by STAT3 provides a novel mechanism for immuno-neuroendocrine interfacing. , 2000, The Journal of clinical investigation.

[8]  J. Tavernier,et al.  Identification of the Y985 and Y1077 motifs as SOCS3 recruitment sites in the murine leptin receptor , 2000, FEBS letters.

[9]  S. Melmed,et al.  Leukemia Inhibitory Factor Mediates the Hypothalamic Pituitary Adrenal Axis Response to Inflammation* * This work was supported by NIDDK Grants DK-54862-02 (to V.C.) and 501238 (to S.M.) and the Doris Factor Molecular Endocrinology Laboratory. , 2000, Endocrinology.

[10]  M. Edery,et al.  Potentiation of growth hormone-induced liver suppressors of cytokine signaling messenger ribonucleic acid by cytokines. , 2000, Endocrinology.

[11]  C. Kedinger,et al.  Role of suppressors of cytokine signaling ( Socs ) in leukemia inhibitory factor ( LIF )-dependent embryonic stem cell survival , 2000 .

[12]  J. G. Zhang,et al.  Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Melmed,et al.  Leukemia-inhibitory factor-neuroimmune modulator of endocrine function. , 2000, Endocrine reviews.

[14]  Alexander S. Banks,et al.  Activation of Downstream Signals by the Long Form of the Leptin Receptor* , 2000, The Journal of Biological Chemistry.

[15]  S. Melmed,et al.  Leukemia inhibitory factor mediates the hypothalamic pituitary adrenal axis response to inflammation. , 2000, Endocrinology.

[16]  W. Leonard,et al.  The Jak-STAT pathway. , 2000, Molecular immunology.

[17]  S. Rivest,et al.  Selective involvement of interleukin-6 in the transcriptional activation of the suppressor of cytokine signaling-3 in the brain during systemic immune challenges. , 2000, Endocrinology.

[18]  R. Wilkins,et al.  STAT5b mediates the GH-induced expression of SOCS-2 and SOCS-3 mRNA in the liver , 1999, Molecular and Cellular Endocrinology.

[19]  D. Waxman,et al.  SOCS/CIS Protein Inhibition of Growth Hormone-stimulated STAT5 Signaling by Multiple Mechanisms* , 1999, The Journal of Biological Chemistry.

[20]  S. Melmed,et al.  Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor. , 1999, The Journal of clinical investigation.

[21]  J. Flier,et al.  The Role of SOCS-3 in Leptin Signaling and Leptin Resistance* , 1999, The Journal of Biological Chemistry.

[22]  A. Yoshimura,et al.  Thrombopoietin induces an SH2-containing protein, CIS1, which binds to Mpl: involvement of the ubiquitin proteosome pathway. , 1999, Experimental hematology.

[23]  P. Heinrich,et al.  Different protein turnover of interleukin-6-type cytokine signalling components. , 1999, European journal of biochemistry.

[24]  P. Kelly,et al.  Inhibition and Restoration of Prolactin Signal Transduction by Suppressors of Cytokine Signaling* , 1999, The Journal of Biological Chemistry.

[25]  J. Gustafsson,et al.  Cis desensitizes GH induced Stat5 signaling in rat liver cells , 1999, Molecular and Cellular Endocrinology.

[26]  P. Kelly,et al.  Dual effects of suppressor of cytokine signaling (SOCS‐2) on growth hormone signal transduction , 1999, FEBS letters.

[27]  S. Melmed,et al.  Autoregulation of pituitary corticotroph SOCS-3 expression: characterization of the murine SOCS-3 promoter. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Melmed,et al.  Critical Role for STAT3 in Murine Pituitary Adrenocorticotropin Hormone Leukemia Inhibitory Factor Signaling* , 1999, The Journal of Biological Chemistry.

[29]  S. Melmed,et al.  Interleukin-11 stimulates proopiomelanocortin gene expression and adrenocorticotropin secretion in corticotroph cells: evidence for a redundant cytokine network in the hypothalamo-pituitary-adrenal axis. , 1999, Endocrinology.

[30]  J. G. Zhang,et al.  The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[31]  A. Yoshimura,et al.  The JAK‐binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop , 1999, The EMBO journal.

[32]  W. Alexander,et al.  Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL‐6 signal transduction , 1999, The EMBO journal.

[33]  Y. Mao,et al.  Endotoxin-induced inhibition of growth hormone receptor signaling in rat liver in vivo. , 1999, Endocrinology.

[34]  K. Shuai,et al.  The Suppressor of Cytokine Signaling (SOCS) 1 and SOCS3 but Not SOCS2 Proteins Inhibit Interferon-mediated Antiviral and Antiproliferative Activities* , 1998, The Journal of Biological Chemistry.

[35]  C. Readhead,et al.  Pituitary-directed leukemia inhibitory factor transgene causes Cushing's syndrome: neuro-immune-endocrine modulation of pituitary development. , 1998, Molecular endocrinology.

[36]  F. Gouilleux,et al.  A Sequence of the CIS Gene Promoter Interacts Preferentially with Two Associated STAT5A Dimers: a Distinct Biochemical Difference between STAT5A and STAT5B , 1998, Molecular and Cellular Biology.

[37]  S. Melmed,et al.  Pituitary corticotroph SOCS-3: novel intracellular regulation of leukemia-inhibitory factor-mediated proopiomelanocortin gene expression and adrenocorticotropin secretion. , 1998, Molecular endocrinology.

[38]  S. Melmed,et al.  Murine leukemia inhibitory factor gene disruption attenuates the hypothalamo-pituitary-adrenal axis stress response. , 1998, Endocrinology.

[39]  S. Melmed,et al.  Leukemia Inhibitory Factor Modulates Interleukin-1β-Induced Activation of the Hypothalamo-Pituitary-Adrenal Axis. , 1998, Endocrinology.

[40]  J. Flier,et al.  Identification of SOCS-3 as a potential mediator of central leptin resistance. , 1998, Molecular cell.

[41]  D. Hilton,et al.  Growth Hormone Preferentially Induces the Rapid, Transient Expression of SOCS-3, a Novel Inhibitor of Cytokine Receptor Signaling* , 1998, The Journal of Biological Chemistry.

[42]  W. Alexander,et al.  Twenty proteins containing a C-terminal SOCS box form five structural classes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[43]  S. Melmed,et al.  Leukemia inhibitory factor modulates interleukin-1beta-induced activation of the hypothalamo-pituitary-adrenal axis. , 1998, Endocrinology.

[44]  U. Ikeda,et al.  SOCS-1/JAB/SSI-1 Can Bind to and Suppress Tec Protein-tyrosine Kinase* , 1997, The Journal of Biological Chemistry.

[45]  D. Ray,et al.  Cytokine-dependent gp130 receptor subunit regulates human fetal pituitary adrenocorticotropin hormone and growth hormone secretion. , 1997, The Journal of clinical investigation.

[46]  Takaho A. Endo,et al.  A new protein containing an SH2 domain that inhibits JAK kinases , 1997, Nature.

[47]  Warren S. Alexander,et al.  A family of cytokine-inducible inhibitors of signalling , 1997, Nature.

[48]  A. Yoshimura,et al.  CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. , 1997, Blood.

[49]  D. Ray,et al.  A Common Pro-opiomelanocortin-binding Element Mediates Leukemia Inhibitory Factor and Corticotropin-releasing Hormone Transcriptional Synergy* , 1997, The Journal of Biological Chemistry.

[50]  S. Melmed,et al.  Leukemia inhibitory factor (LIF) induces acute adrenocorticotrophic hormone (ACTH) secretion in fetal rhesus macaque primates: a novel dynamic test of pituitary function. , 1996, The Journal of clinical endocrinology and metabolism.

[51]  J. Ihle,et al.  Naturally occurring dominant negative variants of Stat5 , 1996, Molecular and cellular biology.

[52]  S. Melmed,et al.  Hypothalamic and pituitary leukemia inhibitory factor gene expression in vivo: a novel endotoxin-inducible neuro-endocrine interface. , 1996, Endocrinology.

[53]  S. Melmed,et al.  Disrupted murine leukemia inhibitory factor (LIF) gene attenuates adrenocorticotropic hormone (ACTH) secretion. , 1996, Endocrinology.

[54]  D. Ray,et al.  Leukemia inhibitory factor (LIF) stimulates proopiomelanocortin (POMC) expression in a corticotroph cell line. Role of STAT pathway. , 1996, The Journal of clinical investigation.

[55]  S. Melmed,et al.  Human and murine pituitary expression of leukemia inhibitory factor. Novel intrapituitary regulation of adrenocorticotropin hormone synthesis and secretion. , 1995, The Journal of clinical investigation.